Fantastic result overnight. Now Covid ARDS Interim readout is the next cab of the rank. Holders can give themselves a well deserved pat on the back (I checked and that is allowed under Covid lockdown rules) but don't get too comfy as the next exciting instalment is already shaping up.
Let's assume for one moment some of the things we learnt from the Ryoncil ADCOM apply equally to ARDS.
MSB set out a clear MOA for Remestemcel-L (I think that was well understood and well received by the committee and by the FDA).
And if that MOA is as effective in ARDS as it is in paediatric AGVHD ............
Then it's going to be a very very interesting couple of weeks. Let's see what the Seppos make of todays outcome first..
GLTAH, commiserations to the watchers for missing out this time, but please note another BIGGER opportunity could be coming right up.
COVID ARDS interim analysis, page-38
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |